Net Income (Loss) Attributable to Parent in USD of Apellis Pharmaceuticals, Inc. from 2015 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Apellis Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from 2015 to Q3 2025.
  • Apellis Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was $216M.
  • Apellis Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was $45M.
  • Apellis Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$198M, a 62.6% increase from 2023.
  • Apellis Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$529M, a 18.9% increase from 2022.
  • Apellis Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$652M, a 12.6% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Apellis Pharmaceuticals, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $45M $216M +$273M 01 Jul 2025 30 Sep 2025 10-Q 30 Oct 2025
Q2 2025 -$228M -$42.2M -$4.49M -11.9% 01 Apr 2025 30 Jun 2025 10-Q 30 Oct 2025
Q1 2025 -$224M -$92.2M -$25.8M -38.8% 01 Jan 2025 31 Mar 2025 10-Q 30 Oct 2025
Q4 2024 -$198M -$36.4M +$52.2M +59% 01 Oct 2024 31 Dec 2024 10-K 28 Feb 2025
Q3 2024 -$250M -$57.4M +$82.8M +59% 01 Jul 2024 30 Sep 2024 10-Q 30 Oct 2025
Q2 2024 -$333M -$37.7M +$84.4M +69.1% 01 Apr 2024 30 Jun 2024 10-Q 30 Oct 2025
Q1 2024 -$417M -$66.4M +$111M +62.6% 01 Jan 2024 31 Mar 2024 10-Q 30 Oct 2025
Q4 2023 -$529M -$88.6M +$77.4M +46.6% 01 Oct 2023 31 Dec 2023 10-K 28 Feb 2025
Q3 2023 -$606M -$140M +$51M +26.7% 01 Jul 2023 30 Sep 2023 10-Q 05 Nov 2024
Q2 2023 -$657M -$122M +$33.9M +21.8% 01 Apr 2023 30 Jun 2023 10-Q 05 Nov 2024
Q1 2023 -$691M -$178M -$38.8M -28% 01 Jan 2023 31 Mar 2023 10-Q 05 Nov 2024
Q4 2022 -$652M -$166M -$18.1M -12.2% 01 Oct 2022 31 Dec 2022 10-K 28 Feb 2025
Q3 2022 -$634M -$191M +$4.3M +2.2% 01 Jul 2022 30 Sep 2022 10-Q 01 Nov 2023
Q2 2022 -$638M -$156M +$63.2M +28.8% 01 Apr 2022 30 Jun 2022 10-Q 01 Nov 2023
Q1 2022 -$702M -$139M +$44.7M +24.4% 01 Jan 2022 31 Mar 2022 10-Q 01 Nov 2023
Q4 2021 -$746M -$148M -$226M -289% 01 Oct 2021 31 Dec 2021 10-K/A 29 Feb 2024
Q3 2021 -$520M -$196M -$59.9M -44.1% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022
Q2 2021 -$460M -$219M -$101M -84.8% 01 Apr 2021 30 Jun 2021 10-Q 07 Nov 2022
Q1 2021 -$360M -$184M -$14.8M -8.79% 01 Jan 2021 31 Mar 2021 10-Q 07 Nov 2022
Q4 2020 -$345M $78.3M +$191M 01 Oct 2020 31 Dec 2020 10-K 25 Feb 2021
Q3 2020 -$536M -$136M -$65.9M -94.3% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021
Q2 2020 -$470M -$119M -$47.5M -66.9% 01 Apr 2020 30 Jun 2020 10-Q 08 Nov 2021
Q1 2020 -$423M -$169M -$118M -234% 01 Jan 2020 31 Mar 2020 10-Q 08 Nov 2021
Q4 2019 -$305M -$113M -$76.8M -211% 01 Oct 2019 31 Dec 2019 10-K 25 Feb 2021
Q3 2019 -$228M -$69.8M -$33.9M -94.1% 01 Jul 2019 30 Sep 2019 10-K 25 Feb 2021
Q2 2019 -$194M -$71.1M -$37.8M -113% 01 Apr 2019 30 Jun 2019 10-K 25 Feb 2021
Q1 2019 -$156M -$50.6M -$28.8M -133% 01 Jan 2019 31 Mar 2019 10-K 25 Feb 2021
Q4 2018 -$128M -$36.5M -$18.2M -99.7% 01 Oct 2018 31 Dec 2018 10-K 27 Feb 2020
Q3 2018 -$109M -$36M -$24.4M -211% 01 Jul 2018 30 Sep 2018 10-K 27 Feb 2020
Q2 2018 -$84.9M -$33.3M -$21.2M -175% 01 Apr 2018 30 Jun 2018 10-K 27 Feb 2020
Q1 2018 -$63.7M -$21.7M -$12.7M -140% 01 Jan 2018 31 Mar 2018 10-K 27 Feb 2020
Q4 2017 -$51M -$18.3M -$11.6M -176% 01 Oct 2017 31 Dec 2017 10-K 26 Feb 2019
Q3 2017 -$39.4M -$11.6M -$4.36M -60.5% 01 Jul 2017 30 Sep 2017 10-K 26 Feb 2019
Q2 2017 -$35M -$12.1M -$4.83M -66.2% 01 Apr 2017 30 Jun 2017 10-K 26 Feb 2019
Q1 2017 -$30.2M -$9.05M -$3.05M -50.9% 01 Jan 2017 31 Mar 2017 10-K 26 Feb 2019
Q4 2016 -$27.1M -$6.62M 01 Oct 2016 31 Dec 2016 10-K 19 Mar 2018
Q3 2016 -$7.21M 01 Jul 2016 30 Sep 2016 10-K 19 Mar 2018
Q2 2016 -$7.29M 01 Apr 2016 30 Jun 2016 10-K 19 Mar 2018
Q1 2016 -$6M 01 Jan 2016 31 Mar 2016 10-K 19 Mar 2018

Apellis Pharmaceuticals, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$198M +$331M +62.6% 01 Jan 2024 31 Dec 2024 10-K 28 Feb 2025
2023 -$529M +$124M +18.9% 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2025
2022 -$652M +$94.2M +12.6% 01 Jan 2022 31 Dec 2022 10-K 28 Feb 2025
2021 -$746M -$401M -116% 01 Jan 2021 31 Dec 2021 10-K/A 29 Feb 2024
2020 -$345M -$40.2M -13.2% 01 Jan 2020 31 Dec 2020 10-K 21 Feb 2023
2019 -$305M -$177M -139% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022
2018 -$128M -$76.5M -150% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021
2017 -$51M -$23.9M -88% 01 Jan 2017 31 Dec 2017 10-K 27 Feb 2020
2016 -$27.1M +$19.4M +41.7% 01 Jan 2016 31 Dec 2016 10-K 26 Feb 2019
2015 -$46.5M 01 Jan 2015 31 Dec 2015 10-K 19 Mar 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.